Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Effect of REcombinant Human Thrombopoietin (rhTPO) on Sepsis Patients With aCUte Severe thrombocytopEnia
Sponsor: Ruilan Wang
Summary
The purpose of this study is to determine whether recombinant human thrombopoietin(rhTPO) can rapidly increase the platelets counts, shorten the time of the platelet returned to normal, reduce platelet transfusion and bleeding events, prompt recovery of organ function, decrease the length of ICU stay, and eventually reduce the 28-day mortality in sepsis patients with severe thrombocytopenia.
Official title: The Effect of Recombinant Human Thrombopoietin(rhTPO) on Sepsis Patients With Acute Severe Thrombocytopenia：a Prospective, Multi-center, Open-label, ,Randomized, Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2019-04-01
Completion Date
2024-09-30
Last Updated
2024-04-18
Healthy Volunteers
No
Conditions
Interventions
rhTPO
Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days
Placebo
The control group will not use any platelet-increased drugs.
Locations (1)
Shanghai General Hospital, Shanghai Jiaotong University
Shanghai, Shanghai Municipality, China